TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15361758

Group type: EXPERIMENTAL
Intervention: Light exercise (LITE) at 40% of maximal oxygen consumption
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Moderate exercise (MOD) at 60% of maximal oxygen consumption
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control session (no exercise)
Number of subjects: 49
Study: 11144006

Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg twice daily for 6 months)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no cisapride)
Number of subjects: 40
Study: 9291422

Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: terfenadine 60 mg
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: loratadine 10 mg
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: astemizole 10 mg
Number of subjects: 111

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 111
Study: 8100688

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1.0 micrograms.kg-1
Number of subjects: 35

Group type: COMPARATOR
Intervention: Dexmedetomidine 0.25, 0.5, 0.75, 1.0 and 1.5 micrograms.kg-1
Number of subjects: 35
Study: 2906345

Group type: EXPERIMENTAL
Intervention: GTD-containing pill
Number of subjects: 176

Group type: COMPARATOR
Intervention: LNG-containing pill
Number of subjects: 176
Study: 28832435

Group type: EXPERIMENTAL
Intervention: Reengagement Outreach (RO) group
Number of subjects: 3020

Group type: COMPARATOR
Intervention: Comparison (no outreach) group
Number of subjects: 3020
Study: 28095580

Group type: EXPERIMENTAL
Intervention: Non-hydroquinone lightening product (JM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 4% Hydroquinone lightening solution (OB)
Number of subjects: 0
Study: 25137843

Group type: EXPERIMENTAL
Intervention: Jiawei Shentong Zhuyu Decoction (JSZD), one dose per day, taken in two portions (morning and evening) for 30 days
Number of subjects: 100

Group type: COMPARATOR
Intervention: Celecoxib Capsule (200 mg once per day) and Mecobalamin Tablet (0.5 mg three times per day, only Mecobalamin from day 11) for 30 days
Number of subjects: 100
Study: 22265118

Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Nutrition counseling
Number of subjects: 44
Study: 20384423

Group type: EXPERIMENTAL
Intervention: Nicotine (1.14 mg nicotine, 15.9 mg tar)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Denicotinized cigarettes (.06 mg nicotine, 17.9 mg tar)
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Alcohol (men: 0.8 g/kg; women: 0.7 g/kg)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 127
Study: 18520312

Group type: EXPERIMENTAL
Intervention: Chronic care intervention for depression treatment
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Summary measure of beliefs
Number of subjects: 395

Group type: COMPARATOR
Intervention: Treatment as usual (control)
Number of subjects: 395
Study: 15992557

Group type: EXPERIMENTAL
Intervention: Hamilton Rating Scale for Depression (HRSD(24)) early insomnia items
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Hamilton Rating Scale for Depression (HRSD(24)) middle insomnia items
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Hamilton Rating Scale for Depression (HRSD(24)) late insomnia items
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Inventory of Depression Symptoms - Self Report (IDS-SR(30)) early insomnia items
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Inventory of Depression Symptoms - Self Report (IDS-SR(30)) middle insomnia items
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Inventory of Depression Symptoms - Self Report (IDS-SR(30)) late insomnia items
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Daily sleep efficiency
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Unit increments in HRSD(24) scores for early, middle, and late insomnia
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Unit increments in IDS-SR(30) scores for early insomnia
Number of subjects: 397
Study: 12495099

Group type: EXPERIMENTAL
Intervention: Double-gloving
Number of subjects: 170

Group type: COMPARATOR
Intervention: Single gloves
Number of subjects: 170
Study: 10525141

Group type: EXPERIMENTAL
Intervention: 50 mg/day of alpha-tocopherol
Number of subjects: 1484

Group type: EXPERIMENTAL
Intervention: 20 mg/day of beta-carotene
Number of subjects: 1484

Group type: EXPERIMENTAL
Intervention: Both alpha-tocopherol and beta-carotene
Number of subjects: 1484

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1484
Study: 7723385

Group type: EXPERIMENTAL
Intervention: Low-dose monthly maintenance therapy
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Late intensification plus monthly maintenance
Number of subjects: 522

Group type: COMPARATOR
Intervention: Late intensification alone
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Allogeneic marrow transplantation in first CR
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Patients with donors not transplanted in first CR
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Patients less than age 50 without donors
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Diagnosis of M3 AML
Number of subjects: 522
Study: 1904551

Group type: EXPERIMENTAL
Intervention: Ribavirin (20 mg per milliliter) administered continuously in aerosolized form
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 7392895

Group type: EXPERIMENTAL
Intervention: Bicycling
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Tennis
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Jogging
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control
Number of subjects: 38
Study: 30274549

Group type: EXPERIMENTAL
Intervention: CGBP + MP + BP with barbell (O1)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: BP positioned last in the sequence (O1 and O3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CGBP (O1 and O3)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: CGBP with Smith machine
Number of subjects: 12
Study: 31012909

Group type: EXPERIMENTAL
Intervention: Lanadelumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 28350280

Group type: EXPERIMENTAL
Intervention: Hypothermia (33–34°C)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control (hemicraniectomy alone)
Number of subjects: 111
Study: 25957663

Group type: EXPERIMENTAL
Intervention: Text message immunization reminders
Number of subjects: 57

Group type: COMPARATOR
Intervention: Healthy baby messages (Control)
Number of subjects: 57
Study: 24624851

Group type: EXPERIMENTAL
Intervention: Nefopam and PCA with Trimeperidine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ketoprofen (100 microg each 12 hours intramuscular) and PCA with Trimeperidine
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Nefopam, Ketoprofen and PCA with Trimeperidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: PCA with Trimeperidine as monotherapy
Number of subjects: 80
Study: 21352357

Group type: EXPERIMENTAL
Intervention: Hypotonic fluids (50-70 mmol/L tonicity)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Isotonic fluids (156 mmol/L tonicity)
Number of subjects: 125
Study: 19720211

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:100,000 epinephrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with 1:50,000 epinephrine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 3% mepivacaine
Number of subjects: 60
Study: 17473654

Group type: EXPERIMENTAL
Intervention: Pemetrexed (500 mg/m intravenously [IV] supplemented with vitamin B12 injections and oral folic acid)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m IV)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 541
Study: 15212837

Group type: EXPERIMENTAL
Intervention: Lipoprotein-depleted plasma
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lipoprotein-free sAbeta
Number of subjects: 0
Study: 11824878

Group type: EXPERIMENTAL
Intervention: 5-HT3 antagonists (specific drugs not mentioned)
Number of subjects: 274

Group type: EXPERIMENTAL
Intervention: Granisetron
Number of subjects: 274
Study: 9686732

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 299

Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 299
Study: 8021375

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50 micrograms/gm) combined with cyclosporine (2 mg/kg/day)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo ointment (vehicle of calcipotriol) combined with cyclosporine (2 mg/kg/day)
Number of subjects: 69
Study: 2671217

Group type: EXPERIMENTAL
Intervention: Guillotine tonsillectomy
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dissection tonsillectomy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Guillotine tonsillectomy (in adults)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Dissection tonsillectomy (in adults)
Number of subjects: 120
Study: 1095118

Group type: EXPERIMENTAL
Intervention: Endoscopy
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Radiology
Number of subjects: 113

Group type: COMPARATOR
Intervention: Biopsy
Number of subjects: 113

Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 113

Group type: COMPARATOR
Intervention: Clinical examination
Number of subjects: 113

Group type: COMPARATOR
Intervention: Multifactorial computer analysis
Number of subjects: 113
Study: 31378074

Group type: EXPERIMENTAL
Intervention: Digital tools for integrated personalized diabetes management (iPDM)
Number of subjects: 907
Study: 31042581

Group type: EXPERIMENTAL
Intervention: Pegylated Interferon-alpha (PegIFN)
Number of subjects: 1823

Group type: COMPARATOR
Intervention: Nucleos(t)ide analogues (NUCs)
Number of subjects: 1823
Study: 28159005

Group type: EXPERIMENTAL
Intervention: Women's Wellness after Cancer Program (WWACP) - a digitised multimodal lifestyle intervention focusing on health education and promotion over 12 weeks.
Number of subjects: 351
Study: 27012084

Group type: EXPERIMENTAL
Intervention: Surgical procedure A (specific procedure not detailed)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Surgical procedure B (specific procedure not detailed)
Number of subjects: 94
Study: 23114568

Group type: EXPERIMENTAL
Intervention: Individuals with Asperger's syndrome (AS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 0
Study: 21207250

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 18292438

Group type: EXPERIMENTAL
Intervention: Clonidine infusion at a rate ranging from 6 to 10 microg x kg(‐1) x h(‐1)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Clonidine infusion
Number of subjects: 6
Study: 15653651

Group type: EXPERIMENTAL
Intervention: Radiosynovectomy (RSV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Local instillation of radiopharmaceuticals
Number of subjects: 0
Study: 14522736

Group type: EXPERIMENTAL
Intervention: Iron supplementation (30 mg Fe as ferrous sulfate)
Number of subjects: 513

Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 513

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 513
Study: 10762110

Group type: EXPERIMENTAL
Intervention: Zanamivir 10 mg via Diskhaler twice daily for 5 days
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Zanamivir
Number of subjects: 356
Study: 8697891

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg b.d.)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amoxycillin (1 g t.d.s.)
Number of subjects: 0
Study: 1618211

Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg per day
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 57
Study: 6376210

Group type: EXPERIMENTAL
Intervention: Oral N-acetylcysteine (Fabrol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29494476

Group type: COMPARATOR
Intervention: SIT
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: STAND
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BOARD
Number of subjects: 30
Study: 27189956

Group type: EXPERIMENTAL
Intervention: Ethanol
Number of subjects: 30

Group type: COMPARATOR
Intervention: DMSO
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DMSO (secondary attempt with ethanol)
Number of subjects: 30
Study: 24662153

Group type: EXPERIMENTAL
Intervention: Three triangular dermal flaps technique
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control series (standard technique)
Number of subjects: 50
Study: 23046783

Group type: EXPERIMENTAL
Intervention: Emotion-focused group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fact-focused group
Number of subjects: 0
Study: 20298996

Group type: EXPERIMENTAL
Intervention: Primary percutaneous coronary intervention (PCI) in patients with prior CABG
Number of subjects: 128

Group type: COMPARATOR
Intervention: Primary percutaneous coronary intervention (PCI) in patients without prior CABG
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: IRA as a bypass graft in prior CABG patients
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: IRA as a native vessel in prior CABG patients
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 90-day mortality in prior CABG patients
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Composite 90-day death/congestive heart failure/shock in prior CABG patients
Number of subjects: 128
Study: 18843433

Group type: EXPERIMENTAL
Intervention: 6 months exercise training
Number of subjects: 60
Study: 15959799

Group type: EXPERIMENTAL
Intervention: Trained runners
Number of subjects: 20
Study: 12634981

Group type: EXPERIMENTAL
Intervention: Digoxin therapy
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 11262673

Group type: EXPERIMENTAL
Intervention: Individually focused intervention (n=48)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Family focused intervention (n=49)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Both interventions (family and individually focused)
Number of subjects: 97
Study: 9543661

Group type: EXPERIMENTAL
Intervention: Parenting intervention
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Assessment participation
Number of subjects: 1121

Group type: EXPERIMENTAL
Intervention: Intervention enrollment
Number of subjects: 1121
Study: 8448458

Group type: EXPERIMENTAL
Intervention: Electronic diaries
Number of subjects: 24

Group type: COMPARATOR
Intervention: Pencil and paper diaries
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both diary methods
Number of subjects: 24
Study: 3915163

Group type: EXPERIMENTAL
Intervention: Dipyridamole (single dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dipyridamole (multidose, three times daily)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (single dose)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (multidose, three times daily)
Number of subjects: 24
Study: 29791315

Group type: EXPERIMENTAL
Intervention: Clinical chorioamnionitis
Number of subjects: 9391
Study: 27816696

Group type: EXPERIMENTAL
Intervention: 20 mg methylphenidate
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 40 mg methylphenidate
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 24858952

Group type: EXPERIMENTAL
Intervention: 50% reduced rapid-acting insulin dose
Number of subjects: 8

Group type: COMPARATOR
Intervention: Full rapid-acting insulin dose
Number of subjects: 8
Study: 22548359

Group type: EXPERIMENTAL
Intervention: Bovine-derived xenograft (BDX)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Autogenous bone (AB)
Number of subjects: 45
Study: 20302978

Group type: EXPERIMENTAL
Intervention: Protective analgesia (1.6g modified release ibuprofen)
Number of subjects: 122

Group type: COMPARATOR
Intervention: Conventional analgesia (400mg conventional ibuprofen)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Protective analgesia
Number of subjects: 122

Group type: COMPARATOR
Intervention: Conventional analgesia
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 122
Study: 18328014

Group type: EXPERIMENTAL
Intervention: Flaxseed (30 g daily for 3 months)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Flaxseed + additional oat bran fiber (not specified)
Number of subjects: 55
Study: 15883267

Group type: EXPERIMENTAL
Intervention: 44 microg TIW
Number of subjects: 605

Group type: COMPARATOR
Intervention: 30 microg QW to 44 microg TIW
Number of subjects: 605
Study: 12860897

Group type: EXPERIMENTAL
Intervention: Tissue Doppler imaging (TDI) in subjects with mutations
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 12
Study: 10100079

Group type: EXPERIMENTAL
Intervention: 0.02 mg ethinyloestradiol
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2.5 mg oestrone sulphate
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 0.625 mg oestrone sulphate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: High-dose oestrone
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Semisynthetic oestrogen
Number of subjects: 24
Study: 8914356

Group type: EXPERIMENTAL
Intervention: Topical fluticasone propionate 0.05% cream
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 1796230

Group type: EXPERIMENTAL
Intervention: Ivermectin at 100 mcg/kg
Number of subjects: 1979

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC) at 3 and 6 mg/kg
Number of subjects: 1979

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1979
Study: 6095635

Group type: EXPERIMENTAL
Intervention: Oat-bran diet
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Bean diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 20
Study: 30653044

Group type: EXPERIMENTAL
Intervention: SMS bot intervention group
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 159
Study: 30138012

Group type: EXPERIMENTAL
Intervention: Sustain group (internal supervision)
Number of subjects: 168

Group type: COMPARATOR
Intervention: External Supervision group (external supervision)
Number of subjects: 168
Study: 27108247

Group type: EXPERIMENTAL
Intervention: Coronary artery disease (CAD) history
Number of subjects: 4038
Study: 25251800

Group type: EXPERIMENTAL
Intervention: Rowing exercise regimen using a rowing ergometer
Number of subjects: 29

Group type: COMPARATOR
Intervention: Chest physical therapy program
Number of subjects: 29
Study: 22265215

Group type: EXPERIMENTAL
Intervention: Structured Self-Monitoring of Blood Glucose (SMBG)
Number of subjects: 483

Group type: COMPARATOR
Intervention: Control group (ACG)
Number of subjects: 483
Study: 20136919

Group type: EXPERIMENTAL
Intervention: Topical Boswellic acids (0.5% BAs)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (base cream without BAs)
Number of subjects: 15
Study: 18377783

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diets
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-fat diets
Number of subjects: 0
Study: 15814545

Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 205

Group type: COMPARATOR
Intervention: Cyclosporin microemulsion (ME)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Both tacrolimus and cyclosporin-ME
Number of subjects: 205
Study: 12168963

Group type: EXPERIMENTAL
Intervention: N2O pneumoperitoneum
Number of subjects: 103

Group type: COMPARATOR
Intervention: CO2 pneumoperitoneum
Number of subjects: 103

Group type: COMPARATOR
Intervention: Postoperative narcotic or ketorolac use
Number of subjects: 103
Study: 10745577

Group type: EXPERIMENTAL
Intervention: Ticlopidine treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 25
Study: 7557825

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1974940

Group type: EXPERIMENTAL
Intervention: Ultrasound screening between the 16th and 20th gestational weeks
Number of subjects: 9310

Group type: COMPARATOR
Intervention: Follow-up only (control group)
Number of subjects: 9310

Group type: EXPERIMENTAL
Intervention: Ultrasound screening
Number of subjects: 9310

Group type: EXPERIMENTAL
Intervention: Ultrasound screening (twins)
Number of subjects: 9310

Group type: COMPARATOR
Intervention: Follow-up only (control group, twins)
Number of subjects: 9310
Study: 365775

Group type: EXPERIMENTAL
Intervention: 500 IU of the influenza subunit vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1000 IU of the influenza subunit vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2000 IU of the influenza subunit vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster injection
Number of subjects: 0
Study: 30641707

Group type: EXPERIMENTAL
Intervention: Dyslipidemia prevalence in male subjects
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Dyslipidemia prevalence in female subjects
Number of subjects: 1008
Study: 28278391

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (110/50 μg once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salmeterol/fluticasone (50/500 μg twice daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Salmeterol/fluticasone
Number of subjects: 0
Study: 26133147

Group type: EXPERIMENTAL
Intervention: Free Gingival Graft (FGG)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Modified Apically Repositioned Flap (MARF)
Number of subjects: 15
Study: 23252768

Group type: EXPERIMENTAL
Intervention: BF-200 ALA
Number of subjects: 0

Group type: COMPARATOR
Intervention: MAL
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BF-200 ALA (narrow wavelength LED lamps)
Number of subjects: 0

Group type: COMPARATOR
Intervention: MAL (narrow wavelength LED lamps)
Number of subjects: 0
Study: 21069358

Group type: EXPERIMENTAL
Intervention: TGF-beta 1 levels in patients with AF (n=107)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: TGF-beta 1 levels in patients with aCHF (n=122)
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis for TGF-beta 1
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Correlation of TGF-beta 1 with left atrial diameter
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Correlation of TGF-beta 1 with NT-proBNP
Number of subjects: 401